Pharmeasy to acquire diagnostics chain Thyrocare in a deal worth over Rs 6,300 crore
from Gadgets Now https://ift.tt/3dgHf7Y
5 investors discuss what’s in store for venture debt following SVB’s collapse
There are many questions around the implications of Silicon Valley Bank’s (SVB) collapse that won’t be answered for a long time. But there’s one question that many startups and investors are hoping will get answered sooner rather than later: What happens to venture debt? SVB was one of the larger, if not the largest, providers of venture debt to U.S.-based startups. And now that First Republic Bank has also gone under, that question has spiraled, growing ever more complex. Many startups rely on venture debt: it’s both a cheaper alternative to raising equity and can serve as a capital tool that helps companies build in ways that equity isn’t great for. For some companies in capital-intensive areas like climate, fintech and defense, access to debt is often the only avenue to growth or scale. Thankfully, venture capitalists aren’t too worried about the SVB collapse’s impact on venture debt as a whole. We’re widening our lens, looking for more investors to participate in TechCrunch su...
Comments
Post a Comment